The role of clusterin in brain cell death is contradictory, as both gene-deficiency and overexpression of clusterin inhibic brain damage in mice [29]. Although biomarkers of sepsis are not widely used in research or clinical practice, it is possible to evaluate

the utility of approaches that are currently available. this website The optimal use of biomarkers as surrogates in informing the design of definitive clinical trials presupposes a valid and extensive understanding of the natural history of the biomarker in the population of interest, and how its levels are modified by therapeutic intervention [8]. These data can then be integrated using meta-analytic techniques to evaluate the capacity of a biomarker to predict a clinically important outcome [30]. A methodology for evaluating the level of evidence that a given

check details biomarker might serve as a reliable surrogate outcome measure has recently been proposed, but its utility in the assessment of biomarkers for diseases such as sepsis where mortality is considerable is unknown [31]. In conclusion, we here provide the first clusterin serum analysis of pediatric patients with sepsis and septic shock. We have shown a significant relationship between the levels of clusterin and pediatric patients with septic state. Further studies are required to elucidate the clinical impact of the observed organ-protective properties of clusterin and next studies are needed to examine his potential roles as predictive outcome markers, as well as his precise functional roles in sepsis, or possible therapeutic potential. JZ – study design, data collection and interpretation, literature search, MF – acceptance of final manuscript version. None declared. None declared.

The work described in this article have been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; EU Directive 2010/63/EU for animal experiments; Uniform Requirements for manuscripts submitted to Biomedical journals. The own research were conducted according to the Carbachol Good Clinical Practice guidelines and accepted by local Bioethics Committee, all patients agreed in writing to participation and these researches. “
“Jednym z najczęstszych niepożądanych skutków antybiotykoterapii u dzieci jest biegunka. Definiuje się ją jako oddawanie przez dziecko stolców częściej niż dotychczas i/lub stolców o luźniejszej konsystencji, których pojawianie się ma związek z antybiotykoterapią, a nie można ich wytłumaczyć inną przyczyną. Na związek wystąpienia biegunki z antybiotykoterapią wskazuje okres wystąpienia objawów nie dłuższy niż 6 tygodni od rozpoczęcia stosowania antybiotyku [1]. Najcięższą postacią kliniczną biegunki związanej z antybiotykotetrapią jest rzekomobłoniaste zapalenie jelita grubego wywołane zakażeniem beztlenową bakterią Clostridium difficile.